Chemical industry – Page 80
-
BusinessEMA wrangles restrain trial data progress
Attempts to balance industry and research interests on transparency draw suggestions of improper collusion
-
Business
Ineos takes full control of Styrolution
€1.1bn deal sees BASF complete its planned exit from styrenics joint venture
-
Business
Genentech to buy breast cancer specialist Seragon
$1.7bn deal for hormone receptor-destroying drug pipeline
-
Business
PPG to buy Mexican paints firm Comex
$2.3bn deal expands US firm’s footprint in Central America
-
Business
Bayer to close polycarbonate plant and cut 90 jobs
Firm has already shut Chinese plant, and will also sell off businesses in Australia and New Zealand
-
Business
Inhaled insulin approved in US
European committee recommends approval for generic long-acting insulin
-
Business
Affymax folds after drug withdrawal
Unexplained allergic reactions to anaemia drug prompt firm to dissolve
-
BusinessLithium-ion battery makers look to stimulate electric car production
Tesla Motors opens up patents and manufacturers plan capacity increases
-
OpinionToo big to innovate?
How strong is the correlation between company size and research productivity, asks Derek Lowe
-
Business
Biotech bounced back in 2013, says report
R&D investment increasing, but industry needs to use its cash more wisely
-
Business
Shire fends off AbbVie takeover bid
Board says deal undervalues the company and its growth potential
-
Business
Medtronic to buy Covidien for $43bn
Tax inversion deal continues consolidation theme among medical device makers
-
Business
Novo Nordisk to create 6000 jobs by 2022
Half of the new Danish employees will be in R&D roles
-
BusinessPharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
-
Business
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition
Early-stage drugs complement Merck’s own developmental portfolio
-
Business
Drug giants settle mismarketing lawsuits
Pfizer and GSK settle claims over promoting drugs for unapproved uses in the US
-
Business
Data sharing helps firms reduce Reach animal testing
Alternative in vitro methods slowly gaining traction for some tests
-
Business
Generics giants jostle over pain drug
Mylan and Actavis contest Teva’s generic celecoxib exclusivity
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
Business
Nano risk register not necessary, says BASF
Reach covers the relevant information, and a register risks attracting unwarranted stigma